All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 17th International Conference on Malignant Lymphomas (ICML), the Lymphoma Hub spoke with Paolo Ghia, Vita-Salute San Raffaele, Milan, IT. We asked, What do the long-term trial results show for fixed-duration combinations in first-line chronic lymphocytic lymphoma (CLL) treatment.
Fixed-duration combinations for first-line CLL treatment—what do the long-term trial results show?
Ghia discusses RESONATE (NCT01578707) and CAPTIVATE (NCT02910583), two long term follow-up studies highlighted at ICML evaluating ibrutinib with venetoclax or ofatumumab as a fixed therapy in patients with CLL. Key conclusions discussed are the incidence of adverse events, progression-free survival and overall survival, time to next treatment, and impact of minimum residual disease. He describes these data as favorable for patients with CLL and explains that minimum residual disease status impacts response rates. Further study is required to investigate follow-up treatment options if patients are seen to relapse after 6 years.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox